Immutep Limited (IMMP), a clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced on Wednesday the completion of patient enrolment in the investigator-initiated EFTISARC-NEO Phase II trial.
The trial is designed to evaluate eftilagimod alpha or efti in combination with radiotherapy and KEYTRUDA or pembrolizumab in patients with resectable soft tissue sarcoma or STS.
EFTISARC-NEO is being conducted by the Maria Sklodowska-Curie National Research Institute of Oncology or MSCNRIO in Warsaw, Poland, and has successfully reached its target enrolment of 40 patients.
The trial aims to assess the safety and efficacy of the triple combination therapy in the neoadjuvant setting for STS patients.
Preliminary data, presented at the Connective Tissue Oncology Society or CTOS Annual Meeting in November 2024, indicated a significant increase in tumour hyalinization/fibrosis, a potential indicator of improved survival with the combination treatment compared to radiotherapy alone.
This early endpoint showed a greater than three-fold improvement, with a median 50% hyalinization/fibrosis rate, compared to the historical median of 15% from radiotherapy alone.
The treatment was well tolerated, with no grade =3 toxicities related to efti and pembrolizumab.
Data updates from the EFTISARC-NEO trial are expected in 2025, marking a crucial step in Immutep's efforts to advance novel immunotherapy treatments for cancer.
Currently, IMMP is trading at $1.97 up by 3.40%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.